v3.25.2
Collaborative and Other Relationships - Samsung Bioepis (Details)
$ in Millions
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Dec. 31, 2019
product
Jun. 30, 2025
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2024
USD ($)
Dec. 31, 2024
USD ($)
Collaborative arrangements and non-collaborative arrangement transactions            
Collaboration profit sharing/(loss reimbursement)   $ 75.0 $ 62.4 $ 133.1 $ 128.0  
Samsung Bioepis            
Collaborative arrangements and non-collaborative arrangement transactions            
Collaboration profit sharing/(loss reimbursement)   57.2 $ 55.9 $ 105.2 $ 116.5  
Samsung Bioepis            
Collaborative arrangements and non-collaborative arrangement transactions            
Contingent Commercialized Rights, Number Of Products | product 2          
Expected profit share percentage 45.00%     50.00%    
Impairment of intangible assets (excluding goodwill)           $ 20.2
Estimated additional payments upon achievement of development and commercial milestones           150.0
Collaboration agreement term       5 years    
Option exercise fee       $ 60.0    
Samsung Bioepis | Related Party            
Collaborative arrangements and non-collaborative arrangement transactions            
Accounts receivable   5.0   5.0   7.6
Accounts payable   $ 0.0   $ 0.0   $ 60.8